Platelet soluble CD40l and matrix metalloproteinase 9 activity are proinflammatory mediators in behçet disease patients

Thrombosis and Haemostasis

Volumn 107, Issue 1, 2012, Pages 88-98

  Bello, Ihosvany Fernández ^a   Álvarez, María T ^a   López Longo, Francisco J ^b   Arias Salgado, Elena G ^c   Martín, Mónica ^a   Jiménez Yuste, Víctor ^a   de la Rúa, Ana Rodríguez ^a   Butta, Nora V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Beh et disease; CD40l; Matrix metalloproteinase 9; MEG 01 cells; Platelets

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE AGGREGATION; MALE; MEGAKARYOBLAST; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; UPREGULATION;

ADULT; AGED; ANTIGENS, CD40; BEHCET SYNDROME; BLOOD PLATELETS; CD40 LIGAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEGAKARYOCYTES; MIDDLE AGED; RECOMBINANT PROTEINS; VASCULITIS;

EID: 84855324263     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-08-0556     Document Type: Article

References (56)

1. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. N Engl J Med 1999; 341: 1284-1291.
2. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-1549.
3. Direskeneli H. Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60: 996-1002.
4. Direskeneli H. Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? Rheumatology 2006; 45: 1461-1465.
5. Aukrust P, Waehre T, Damås JK, et al. Inflammatory role of platelets in acute coronary syndromes. Heart 2001; 86: 605-606.
6. Anand SX, Viles-Gonzalez JF, Badimón JJ, et al. Membrane-associated CD40L and sCD40L in atherotrombotic disease. Thromb Haemost. 2003; 90: 377-384.
7. Menchén L, Marín-Jiménez I, Arias-Salgado EG, et al. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 2009; 58: 920-928.
8. Choi WS, Jeon OH, Kim DS. CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3). J Thromb Haemost 2010; 8: 1364-1371.
9. Lievens D, Eijgelaar WJ, Biessen EA, et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
10. Lievens D, Zernecke A, Seijkens T et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
11. Missiou A, Wolf D, Platzer I, et al. CD40L induces inflammation and adipogenesis in adipose cells--a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010; 103: 788-796.
12. Poggi M, Engel D, Christ A, et al. CD40L Deficiency Ameliorates Adipose Tissue Inflammation and Metabolic Manifestations of Obesity in Mice. Arterioscler Thromb Vasc Biol 2011; 31: 2251-2260.
13. Andre P, Nannizzi-Alaimo L, Prasad SK et al. Platelet-derived CD40L: the switchhitting player of cardiovascular disease. Circulation 2002; 106: 896-899.
14. Aukrust P, Müller F, Ueland T, et al. Enhanced levels of soluble and membranebound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
15. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649-655.
16. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, et al. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002; 105: 2849-2854.
17. Kato K, Santana-Sahagún E, Rassenti LZ, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 947-955.
18. Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99: 938-945.
19. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet ́s disease. Lancet 1990; 335: 1078-1080.
20. Bhakta BB, Brennan P, James TE, et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-733.
21. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392.
22. André P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 8: 247-252.
23. Furman MI, Krueger LA, Linden MD, et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43: 2319-2325.
24. Koç Y, Güllü I, Akpek G, et al. Vascular involvement in BD Behçet's disease. J Rheumatol 1992; 19: 402-410.
25. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet's disease. Curr Opin Rheumatol 2005; 17: 1-8.
26. Pay S, Abbasov T, Erdem H, et al. Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation? clin exp rheumatol 2007; 25: s70-75.
27. Descamps FJ, Kangave D, Cauwe B, et al. Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. J Cell Mol Med 2008; 12: 2449-2456.
28. Mason PJ, Chakrabarti S, Albers AA, et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005; 96: 1365-1369.
29. Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99: 2612-2614.
30. Jung K, Mannello F, Lein M. Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles. J Transl Med 2009; 7: 87.
31. Gerlach RF, Demacq C, Jung K, et al. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007; 40: 119-123.
32. Ricart JM, Ramón LA, Vayá A, et al. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. Br J Haematol 2008; 141: 716-719.
33. Yurdakul S, Hekim N, Soysal T, et al. Fibrinolytic activity and D-dimer levels in Behçet's syndrome. Clin Exp Rheumatol 2005; 23: S53-58.
34. Akar S, Ozcan MA, Ates H et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet's disease. Clin Appl Thromb Hemost 2006; 12: 451-457.
35. Martínez M, Ricart JM, Ruiz-Aja S et al. Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behçet's disease: are they related to thrombotic events? Pathophysiol Haemost Thromb 2007; 36: 18-22.
36. Varo N, Libby P, Nuzzo R, et al. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2005, 2: 81-87.
37. Tousoulis D, Zisimos K, Antoniades C, et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: The role of left atrium distension. Int J Cardiol 2009; 136: 258-262.
38. Ohashi Y, Kawashima S, Mori T. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction. Int J Cardiol 2006; 112: 52-58.
39. Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
40. Chen C, Chai H, Wang X. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008; 112: 3205-3216.
41. Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118: 451-457.
42. Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-210.
43. Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: The Opportunities and Challenges. Adv Exp Med Biol 2009; 647: 8-36.
44. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
45. Schönbeck U, Mach F, Sukhova GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997; 81: 448-454.
46. Li G, Sanders JM, Bevard MH, et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 2008; 172: 1141-1152.
47. Smola-Hess S, Schnitzler R, Hadaschik D, et al. CD40L induces matrix-metalloproteinase- 9 but not tissue inhibitor of metalloproteinases-1 in cervical carcinoma cells: imbalance between NF-kappaB and STAT3 activation. Exp Cell Res 2001; 267: 205-215.
48. Lollini PL, Landuzzi L, Frabetti F, et al. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res 1998; 4: 1843-1849.
49. Mach F, Schönbeck U, Fabunmi RP, et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154: 229-238.
50. Baharav E, Weinberger A, Mor F. Experimental models of Behçet's Disease. Drug Disc Today: Dis Models 2006; 3: 11-14.
51. Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
52. Cecchetti L, Tolley ND, Michetti N, et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
53. Zhou L, Ismaili J, Stordeur P, et al. Inhibition of the CD40 pathway of monocyte activation by triazolopyrimidine. Clin Immunol 1999; 93: 232-238.
54. Zhou L, Schandené L, Mordvinov VA, et al. Trapidil inhibits monocyte CD40 expression by preventing IFN-gamma-induced STAT1 S727 phosphorylation. Int Immunopharmacol 2004; 4: 863-871.
55. Kato Y, Tsuda T, Hosaka Y, et al. Effects of trapidil on effector functions of monocytes related to atherosclerotic plaque. Eur J Pharmacol 2001; 428: 371-379.
56. Lutgens E, Lievens D, Beckers L, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.